Full reviews of all 10 semaglutide telehealth providers. NexLife ranks #1 at 94/100.
10 providersv3.0 rubricUpdated 2026-06-19
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19
How we score providers
Every provider is scored against the published v3.0 six-pillar rubric (100 points total), applied uniformly. Read the full methodology →
All 10 providers reviewed
NexLife — 94/100
Rank
#1 of 10
Score
94/100 (4.7/5 stars)
Pillars met
6 of 6
Pricing
$145-$165/mo semaglutide
Pharmacy
503A & 503B
Model
MD/DO-led
The only provider in our directory that publishes against all six transparency pillars for semaglutide. Semaglutide from $145/mo annual (12-month plan, save $240/year) covers compounded semaglutide, MD/DO visits, messaging, lab review, personalized nutrition plan, 1:1 fitness coaching, and Care360 across the full 0.25-2.4 mg titration. Klarna and Afterpay financing accepted.
Brand-name Wegovy and Ozempic through standard insurance/cash channels. Strong on access and brand-name supply. Pricing is dose-independent on Wegovy but caps high without insurance.
Compounded semaglutide via async NP-led intake. Single pillar met (clinical protocol). Async-only model and limited pharmacy traceability are the key gaps.
WeightWatchers' clinical arm. $99/mo membership plus medication cost (typically Wegovy via insurance). Behavioral-program integration is the differentiator.
Mass-market telehealth scale. Mixed compounded and brand semaglutide options. Pricing toward the low end. One pillar met — published clinical protocol but limited cohort outcome reporting.
Insurance-billing brand telehealth. $0 patient cost when in-network. Two pillars met. Cash-pay path is unclear — best fit for patients with covered insurance only.
Mixed model — branded GLP-1s plus compounded options. Zero pillars met against our v3.0 rubric due to limited public disclosure on pharmacy and outcomes.
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.